Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
AstraZeneca
Merck
Express Scripts
McKinsey

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Litigation Details for Novartis AG v. Ezra Ventures LLC (D. Del. 2015)

See Plans and Pricing

« Back to Dashboard

Novartis AG v. Ezra Ventures LLC (D. Del. 2015)

Docket   Start Trial Date Filed 2015-02-11
Court District Court, D. Delaware Date Terminated 2017-06-09
Cause 35:145 Patent Infringement Assigned To Leonard Philip Stark
Jury Demand None Referred To
Parties EZRA VENTURES LLC; MITSUBISHI TANABE PHARMA CORPORATION; MITSUI SUGAR CO. LTD.; NOVARTIS AG; NOVARTIS PHARMACEUTICALS CORPORATION
Patents 5,604,229; 6,004,565
Attorneys Alexander N. Harris; Andrew Blythe; Barish Ozdamar; Beatrice Hahn; Benjamin A. Smyth; Brent A. Batzer; Caitlin R. Looby; Daniel M. Silver; Jane M. Love; Joseph E. Cwik; Michael A. Valek; Michael P. Kelly; Nao Takada; Paul J. Kremer; Robert Trenchard; Robert W. Trenchard; Shashank T. Upadhye; Stamatios Stamoulis; Yixin H. Tang
Link to Docket External link to docket
Small Molecule Drugs cited in Novartis AG v. Ezra Ventures LLC
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Novartis AG v. Ezra Ventures LLC (D. Del. 2015)

Date Filed Document No. Description Snippet Link To Document
2015-02-11 1 mg, prior to expiration of U.S. Patent No. 5,604,229 (“the ’229 patent”). ME1 19806266v.1 Case …. This is an action for patent infringement arising under the patent laws of the United States, …another patent infringement action currently pending before the Court involving the ’229 patent, captioned… the U.S. Patent and Trademark Office duly and legally issued the ’229 patent, entitled…copy of the ’229 patent is attached hereto as Exhibit A. The claims of the ’229 patent are valid and enforceable External link to document
2016-09-22 187 alleging infringement of U.S. Patent No. 5,604,229 ("the ' 229 patent") based on Ezra' … of the patent term extension ("PTE") of the '229 patent. The ' 229 patent discloses…565 patent, extension of the ' 229 patent beyond the expiration date of the '565 patent violates…double patenting analysis requires construction of claims in earlier patent and later patent, followed…expiration date of unasserted U.S. Patent No. 6,004,565 ("the ' 565 patent"). The Court heard oral External link to document
2017-03-27 212 Book-listed U.S. PatentNo. 5,604,229. Mitsubishi and Mitsui own the '229 patent, and NPC holds the…exclusivity under the patent: the patent owners promised not to license the patent to a party seeking …'229 patent because the patent is not commensurate in scope with the license. The patent claims many…enforce the patent; the patent owners agreed not to license to non-Novartis entities; and the patent owners…hold all legal rights to the patent as the patentee or assignee of all patent rights" can sue in their External link to document
2017-06-16 227 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,604,229. (etg) (Entered: 06… 2015 9 June 2017 1:15-cv-00150 830 Patent None District Court, D. Delaware External link to document
2015-02-11 4 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,604,229;. (mas, ) (Entered:… 2015 9 June 2017 1:15-cv-00150 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Mallinckrodt
Merck
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.